VAM
GEVA

Verity Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Verity Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,361
Closed -$219K – 113
2014
Q4 		$219K Buy
+2,361
New +$186K 0.21% 67

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verity Asset Management's GEVA Position: Q1 2015 in Review

Verity Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 2,361 shares — an estimated $219K sold.

Verity Asset Management first reported a position in GEVA in Q4 2014 and held it in 1 quarter. The position peaked at $219K in Q4 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Verity Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Verity Asset Management sold 2,361 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $219K.
  • Verity Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2014 and held it in 1 quarter.
  • Verity Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $219K in Q4 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Verity Asset Management's 13F filing for Q1 2015, filed 15 May 2015.